ECSP20021379A - Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene - Google Patents
Nuevo derivado de fenilpiridina y composición farmacéutica que lo contieneInfo
- Publication number
- ECSP20021379A ECSP20021379A ECSENADI202021379A ECDI202021379A ECSP20021379A EC SP20021379 A ECSP20021379 A EC SP20021379A EC SENADI202021379 A ECSENADI202021379 A EC SENADI202021379A EC DI202021379 A ECDI202021379 A EC DI202021379A EC SP20021379 A ECSP20021379 A EC SP20021379A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical composition
- phenylpyridine
- composition containing
- new derivative
- present disclosure
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000005359 phenylpyridines Chemical class 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente divulgación se refiere a un nuevo derivado de fenilpiridina representado por la Fórmula química 1 y a una composición farmacéutica que comprende el mismo, y el compuesto según la presente divulgación puede usarse de manera útil para la prevención o el tratamiento de enfermedades autoinmunitarias o cánceres.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170131349A KR102613433B1 (ko) | 2017-10-11 | 2017-10-11 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20021379A true ECSP20021379A (es) | 2020-05-29 |
Family
ID=66101569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202021379A ECSP20021379A (es) | 2017-10-11 | 2020-04-07 | Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11149019B2 (es) |
| EP (1) | EP3696176B1 (es) |
| JP (1) | JP6876873B2 (es) |
| KR (2) | KR102613433B1 (es) |
| CN (1) | CN111212833B (es) |
| AU (1) | AU2018349293B2 (es) |
| CA (1) | CA3076667C (es) |
| CL (1) | CL2020000940A1 (es) |
| CO (1) | CO2020004319A2 (es) |
| DO (1) | DOP2020000077A (es) |
| EC (1) | ECSP20021379A (es) |
| ES (1) | ES2915583T3 (es) |
| MA (1) | MA50368A (es) |
| MX (1) | MX2020003616A (es) |
| MY (1) | MY194695A (es) |
| NZ (1) | NZ763263A (es) |
| PE (1) | PE20200848A1 (es) |
| PH (1) | PH12020550252B1 (es) |
| RU (1) | RU2748945C1 (es) |
| SA (1) | SA520411726B1 (es) |
| SG (1) | SG11202002422WA (es) |
| TN (1) | TN2020000050A1 (es) |
| WO (1) | WO2019074275A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200151A (es) | 2017-10-11 | 2020-05-23 | Hoffmann La Roche | Compuestos bicíclicos y métodos de utilización de los mismos |
| KR102328682B1 (ko) | 2018-08-27 | 2021-11-18 | 주식회사 대웅제약 | 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물 |
| CN115151537B (zh) * | 2020-02-26 | 2024-09-06 | 株式会社大熊制药 | 制备杂环胺衍生物的方法 |
| KR102531088B1 (ko) * | 2020-02-26 | 2023-05-10 | 주식회사 대웅제약 | 헤테로사이클릭아민 유도체의 제조 방법 |
| WO2024182552A1 (en) * | 2023-03-01 | 2024-09-06 | Uereka Biosciences, Inc. | Lzk inhibitors |
| CN116535356B (zh) * | 2023-03-06 | 2026-03-17 | 中国药科大学 | 3-氨基-5-苯基-吡唑类衍生物微管蛋白抑制剂及其制备和医药用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3113902A (en) | 2000-12-21 | 2002-07-01 | Bristol Myers Squibb Co | Thiazolyl inhibitors of tec family tyrosine kinases |
| EP1697508A2 (en) | 2003-12-05 | 2006-09-06 | Vertex Pharmaceuticals, Inc. | Crystal structure of interleukin-2 tyrosine kinase (itk) and binding pockets thereof |
| US20070032403A1 (en) | 2003-12-30 | 2007-02-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Crystal structure of the ITK kinase domain |
| TW200738680A (en) | 2005-08-04 | 2007-10-16 | Hoffmann La Roche | Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents |
| TW200811134A (en) * | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| PE20080839A1 (es) | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| PL2526933T3 (pl) * | 2006-09-22 | 2015-08-31 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej Brutona |
| AU2008262291A1 (en) | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| CA2730930C (en) | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
| CA2803056C (en) * | 2010-06-23 | 2017-05-16 | Hanmi Science Co., Ltd. | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| WO2012003283A1 (en) * | 2010-06-30 | 2012-01-05 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
| WO2012035055A1 (en) * | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
| EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| EP2890691B1 (en) * | 2012-08-31 | 2018-04-25 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
| US9296703B2 (en) * | 2012-10-04 | 2016-03-29 | University Of Utah Research Foundation | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors |
| DK3035936T3 (da) | 2013-08-23 | 2019-06-11 | Neupharma Inc | Visse kemiske enheder, sammensætninger og fremgangsmåder |
| KR20160063366A (ko) * | 2013-10-21 | 2016-06-03 | 메르크 파텐트 게엠베하 | Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도 |
| WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| WO2015157556A1 (en) | 2014-04-09 | 2015-10-15 | Kadmon Corporation, Llc | Treatment of gvhd |
| US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
-
2017
- 2017-10-11 KR KR1020170131349A patent/KR102613433B1/ko active Active
-
2018
- 2018-10-11 PE PE2020000589A patent/PE20200848A1/es unknown
- 2018-10-11 ES ES18865651T patent/ES2915583T3/es active Active
- 2018-10-11 RU RU2020115083A patent/RU2748945C1/ru active
- 2018-10-11 AU AU2018349293A patent/AU2018349293B2/en active Active
- 2018-10-11 PH PH1/2020/550252A patent/PH12020550252B1/en unknown
- 2018-10-11 US US16/650,441 patent/US11149019B2/en active Active
- 2018-10-11 MY MYPI2020001499A patent/MY194695A/en unknown
- 2018-10-11 TN TNP/2020/000050A patent/TN2020000050A1/en unknown
- 2018-10-11 MX MX2020003616A patent/MX2020003616A/es unknown
- 2018-10-11 CA CA3076667A patent/CA3076667C/en active Active
- 2018-10-11 EP EP18865651.6A patent/EP3696176B1/en active Active
- 2018-10-11 NZ NZ763263A patent/NZ763263A/en unknown
- 2018-10-11 SG SG11202002422WA patent/SG11202002422WA/en unknown
- 2018-10-11 JP JP2020519093A patent/JP6876873B2/ja active Active
- 2018-10-11 WO PCT/KR2018/011913 patent/WO2019074275A1/ko not_active Ceased
- 2018-10-11 MA MA050368A patent/MA50368A/fr unknown
- 2018-10-11 CN CN201880066324.1A patent/CN111212833B/zh active Active
-
2020
- 2020-04-07 SA SA520411726A patent/SA520411726B1/ar unknown
- 2020-04-07 EC ECSENADI202021379A patent/ECSP20021379A/es unknown
- 2020-04-07 CL CL2020000940A patent/CL2020000940A1/es unknown
- 2020-04-08 CO CONC2020/0004319A patent/CO2020004319A2/es unknown
- 2020-05-06 DO DO2020000077A patent/DOP2020000077A/es unknown
-
2022
- 2022-05-04 KR KR1020220055598A patent/KR20220066012A/ko not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2020000077A (es) | Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene | |
| PH12018502535B1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| MX2019014104A (es) | Compuesto novedoso de bifenilo o sal del mismo. | |
| TW201613911A (en) | Heterocyclic compounds and uses thereof | |
| MX2018006503A (es) | Compuesto novedoso de bifenilo o una sal del mismo. | |
| CO2021001849A2 (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
| DOP2019000193A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| MY189454A (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| MX378732B (es) | Formas solidas novedosas | |
| CL2017001511A1 (es) | Derivados de piperidina como inhibidores de hdac1/2. | |
| EA201991580A1 (ru) | Пиримидиновое соединение и его фармацевтическое применение | |
| PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
| BR112017008481A2 (pt) | composto antimicótico | |
| DOP2019000194A (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| IN2014MU00626A (es) | ||
| MX2019006940A (es) | Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar. | |
| MX2018002177A (es) | Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. | |
| CL2020002347A1 (es) | Nuevo compuesto y composición farmacéutica que lo comprende | |
| UY35095A (es) | Compuestos heterocíclicos que contienen nitrógeno |